Unum Therapeutics is a biopharmaceutical company focused on developing curative cell therapies for solid tumors. Co.'s proprietary technology includes its Bolt-On Chimeric Receptor platform, designed to discover bolt-on transgenes to improve the functionality of engineered T cells and overcome resistance of the solid tumor microenvironment to T cell attack. Co. has also developed product candidates using its proprietary technology, Antibody-Coupled T cell Receptor, an autologous engineered T-cell investigational therapy that is designed to combine the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert antitumor immune responses. We show 12 historical shares outstanding datapoints in our coverage of UMRX's shares outstanding history.
Understanding the changing numbers of UMRX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like UMRX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching UMRX by allowing them to research UMRX shares outstanding history
as well as any other stock in our coverage universe. |
Free UMRX Email Alerts:
Video: Shares Outstanding Importance
